Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma by K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin

Subjects: Get full text

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models by Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago‐Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer‐Meir Salame, Moshit Lindzen, Yosef Yarden

Subjects: Get full text

The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-a... by Weixing Zhao, Bo Li, Yujia Gu, Xiaoni Jin, Zirui Li, Wanjing Guo, Xinxin Lu, Jun Jiang

Subjects: Get full text

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial by Qihua Zou, Yi Cao, Yulin Lai, Yu Fang, Yuchen Zhang, Panpan Liu, Lixia Lu, Hao Wu, Tianying Huang, Ning Su, Zhihua Li, Xicheng Wang, Xiaopeng Tian, Lirong Li, Yingxian Liu, Qingqing Cai, Yi Xia

Subjects: Get full text

Russian observational study of the efficacy and tolerability of depakine chrono as first-line monotherapy for focal epilepsy by E. D. Belousova

Subjects: Get full text

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020 by Laure Vincent, Olivier Decaux, Aurore Perrot, Bruno Royer, Thomas Chalopin, Arthur Bobin, Margaret Macro, Denis Caillot, Lionel Karlin, Caroline Jacquet, Cécile Sonntag, Mohamad Mohty, Laurent Frenzel, Arnaud Jaccard, Salomon Manier, Laurence Sanhes, Driss Chaoui, Philippe Moreau, Ronan Garlantézec, Nathalie Texier, Chanaz Louni, Zakaria Maarouf, Herve Avet Loiseau, Cyrille Hulin, Karim Belhadj Merzoug

Subjects: Get full text

Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma by A. M. Chekalov, M. O. Popova, I. V. Tsygankov, Yu. A. Rogacheva, N. P. Volkov, K. V. Lepik, M. V. Demchenkova, T. V. Schneider, Yu. V. Kopeikina, N. V. Medvedeva, I. S. Zyuzgin, E. S. Pavlyuchenko, A. N. Levanov, A. A. Myasnikov, E. V. Kariagina, N. B. Mikhailova, V. V. Baykov, A. D. Kulagin

Subjects: Get full text

Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data by Zhihao Li, Daniel Aliseda, Owen Jones, Luckshi Rajendran, Christian Magyar, Robert Grant, Grainne M. O’Kane, Anna Saborowski, Gonzalo Sapisochin, Arndt Vogel

Subjects: Get full text

Changing landscape of first-line treatment for locally advanced or metastatic urothelial carcinoma: the progression from platinum-based chemotherapy to platinum-free therapy by Zengguang Liu, Chen Chen, Jiaxin Yin, Xiaofeng Cong, Ziling Liu

Subjects: Get full text

Factors Influencing the Response of Patients with Infantile Epileptic Spasms Syndrome to ACTH as Repeated First-Line Therapy by Wenrong Ge, Ping Pang, Ziyan Zhang, Lin Wan, Guang Yang

Subjects: Get full text

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China by Feng Chen, Xue Feng, Lin Lin Xiao, Hai Juan Tang, Shu Xia Qin, Jie Ping Peng, Jing Bai

Subjects: Get full text

PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort... by Riqing Huang, Haifeng Li, Shuo Li, Ditian Shu, Rishang Chen, Zhousan Zheng, Tinghua Gao, Meiting Chen, Anqi Hu, Yunjie Huang, Qiufan Zheng, Xin An, Cong Xue, Yuchen Cai, Yanxia Shi

Subjects: Get full text

Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic colorectal cancer: real-world evidence and prognostic insight by Chia-Chang Yeh, Shih-Wei Chiang, Shih-Wei Chiang, Feng-Fan Chiang, Feng-Fan Chiang

Subjects: Get full text

A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Popul... by Jad Chidiac, MD, Reine-Marie Kahwaji, MD, Souheil Hallit, PharmD, MSc, MPH, PhD, Yara Yazbeck, MD, Bassem Akiki, MD, Charbel Yazbeck, MD

Subjects: Get full text

The first-line therapy of aggressive non-Hodgkin’s lymphomas in russian clinical practice: data from the EQUILIBRIUM study by L. G. Babicheva, I. V. Poddubnaya

Subjects: Get full text

Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Sco... by Fabrizio Nelli, Enzo Maria Ruggeri, Marta Schirripa, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Daniele Remotti, Agnese Fabbri

Subjects: Get full text

Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol) by E. S. Nesterova, S. K. Kravchenko, A. M. Kovrigina, E. G. Gemdzhian, L. V. Plastinina, Ya. K. Mangasarova, F. E. Babaeva, A. E. Misyurina, O. V. Margolin, A. U. Magomedova, V. I. Vorobiev, D. S. Maryin, E. A. Baryakh, Yu. Yu. Polyakov, P. A. Zeynalova, E. M. Volodicheva, N. N. Glonina, N. V. Minaeva, G. A. Davydova, V. G. Savchenko

Subjects: Get full text

Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer by Christina B. Walter, Andreas D. Hartkopf, Alexander Hein, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Laura L. Michel, Erik Belleville, Hanna Huebner, Sabrina Uhrig, Chloë Goossens, Pauline Wimberger, Carsten Hielscher, Julia Meyer, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Tanja N. Fehm, Carlo Fremd

Subjects: Get full text

Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1^st line... by I. N. Dyakov

Subjects: Get full text

Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina Faso by Rosemonde M. Guissou, Jean Moïse T. Kaboré, Issiaka Soulama, Denise Hien, Yacouba Nombré, Alfred B. Tiono, Christian Burri, Sodiomon B. Sirima

Subjects: Get full text